Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS) Sees Significant Decrease in Short Interest

Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS) saw a significant drop in short interest in the month of April. As of April 15th, there was short interest totaling 8,236 shares, a drop of 21.3% from the March 31st total of 10,469 shares. Approximately 0.0% of the company’s shares are sold short. Based on an average daily trading volume, of 18,266 shares, the days-to-cover ratio is presently 0.5 days.

Hedge Funds Weigh In On Barinthus Biotherapeutics

An institutional investor recently raised its position in Barinthus Biotherapeutics stock. Renaissance Technologies LLC increased its holdings in Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS) by 115.8% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 143,100 shares of the company’s stock after acquiring an additional 76,800 shares during the quarter. Renaissance Technologies LLC owned approximately 0.35% of Barinthus Biotherapeutics worth $100,000 at the end of the most recent quarter. 25.20% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, Weiss Ratings lowered shares of Barinthus Biotherapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, April 22nd. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $4.00.

Barinthus Biotherapeutics Stock Up 5.5%

BRNS traded up $0.03 on Thursday, reaching $0.63. The company’s stock had a trading volume of 16,574 shares, compared to its average volume of 40,165. The stock has a 50 day moving average of $0.60 and a two-hundred day moving average of $0.76. The company has a market capitalization of $25.86 million, a price-to-earnings ratio of -0.38 and a beta of -0.61. Barinthus Biotherapeutics has a fifty-two week low of $0.51 and a fifty-two week high of $2.92.

Barinthus Biotherapeutics (NASDAQ:BRNS) last announced its quarterly earnings results on Thursday, April 30th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.14. As a group, analysts anticipate that Barinthus Biotherapeutics will post -1.42 earnings per share for the current fiscal year.

Barinthus Biotherapeutics Company Profile

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.